North America Non-Invasive Prenatal Testing Market

North America Non-Invasive Prenatal Testing Market Size (2023 to 2028)

The size of the North American Non-Invasive Prenatal Testing Market is estimated to value USD 1.55 billion by 2028 and USD 0.73 billion in 2023, growing at a CAGR of 16.20% during the forecast period.

The market for the non-invasive prenatal testing market is most likely to be driven by a rising preference for non-invasive techniques over invasive methods and growing awareness of non-invasive prenatal testing. Also, the high risk of chromosomal abnormalities with growing maternal age is expected to drive the market. Moreover, improving reimbursement scenarios for Non-Invasive Prenatal Testing and growing product usage in new applications is influencing the market growth in the region. Additionally, advancements in current tests in enhanced functionalities, better chemistry, and bioinformatics analysis are expected to drive market growth.

The benefits of these tests over more comprehensive and invasive procedures like amniocentesis and chronic villus collection have boosted NIPT testing usage. These benefits are more likely to promote the acceptance of such treatments, resulting in the market's rapid growth.

Furthermore, technological advancements in the detection of monogenic diseases enhance market revenue. Progenity, Inc., for example, introduced Resura in April 2019 to enhance its portfolio in contrast to other competitive tests on the market. Resura is a prenatal test for a monogenic illness that utilizes sequencing-based non-invasive cell-free DNA technology.

The American College of Obstetricians and Gynecologists (ACOG) collaborated with the Society for Maternal-Fetal Medicine (SMFM) to release recommendations on aneuploidy screening options, which prompted this coverage (SMFM). One of the market's main driving forces is improving payment policies for ordinary and low-risk pregnancies. For example, Natera announced in December 2020 that their non-invasive prenatal testing (NIPT) would be covered by the most extensive U.S. health plan, Aetna, for all pregnancies.

Owing to the rise in genetic diseases, increased awareness of early fetal testing, and growing maternal age, the market demand for non-invasive prenatal testing is projected to rise over the forecast period. In addition, the developed countries such as the United States and Canada have witnessed advanced healthcare infrastructure, technological advancement in the healthcare sector, which are expected to provide lucrative growth opportunities for the new market entrants.

However, a dearth of skilled professionals is restraining the growth of this market. Also, a lack of test accessibility, ethical issues, and strict government restrictions are only a few reasons that will limit the North American NIPT market's growth.

This research report on the North American Non-Invasive Prenatal Testing Market has been segmented and sub-segmented into the following categories.

By Instruments: 

• Ultrasound
• NGS
• PCR
• Microarray

By Method: 

• FCMB
• Cf-DNA

By Application: 

• Trisomy
• Microdeletion
• Genetics
• Rh Factor

By End User: 

• Hospitals
• Diagnostic Labs

By Country: 

• The United States
• Canada
• Rest of North America

Regionally, North America took the major chunk of the Global Non-Invasive Prenatal Testing Market share in 2022, with the U.S. accounting for a major share.

Globally, North America dominated the Non-Invasive Prenatal Testing Market and accounted for the revenue share of over 45.9 % in 2022. The market growth in the region is attributed to the technological advancements in the healthcare sector, favourable reimbursement policies, and rising preference for non-invasive techniques over invasive methods. Although the United States lacks national consensus policies on NIPT implementation, it is extensively embraced across the country, resulting in North America's dominance. As a result, in the North American regional market, the United States dominated the market growth and held the highest share over the forecast period. The country's major companies concentrate on inorganic strategies with the industry's leading players to enhance their research and commercialization capabilities, which are projected to generate substantial market revenue.

Furthermore, major insurance companies' recent inclusion of NIPT in their coverage plans is expected to promote market growth in the United States. In addition, Illumina won a patent infringement case against Roche's Ariosa Diagnostics (Roche) in June 2019. on the other hand, the Canadian Non-Invasive Prenatal Testing Market is anticipated to account for a moderate share and contribute to the regional market growth. 

KEY MARKET PLAYERS:

A few of the prominent companies operating in the North America Non-Invasive Prenatal Testing Market profiled in the report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).